Trials / Completed
CompletedNCT00002543
Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors
GALLIUM NITRATE FOR THE TREATMENT OF MALIGNANT TUMORS, A PHASE I STUDY
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (estimated)
- Sponsor
- Medical College of Wisconsin · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: : Phase I trial to study the effectiveness of gallium nitrate in young patients who have malignant brain tumors, neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, or refractory solid tumor.
Detailed description
OBJECTIVES: I. Determine the safety and side effects of gallium nitrate (GAN) when used as an anticancer agent in pediatric patients with refractory solid tumors, including malignant brain tumors, neuroblastoma, rhabdomyosarcoma, and non-Hodgkin's lymphoma. II. Evaluate these side effects in these patients. OUTLINE: Single-Agent Chemotherapy. Gallium Nitrate, GAN, NSC-15200. PROJECTED ACCRUAL: At least 3 patients will be accrued at each dose studied.
Conditions
- Brain and Central Nervous System Tumors
- Lymphoma
- Neuroblastoma
- Sarcoma
- Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gallium nitrate |
Timeline
- Start date
- 1995-02-01
- Completion
- 2004-10-01
- First posted
- 2004-10-05
- Last updated
- 2013-07-18
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002543. Inclusion in this directory is not an endorsement.